Special items: Ovarian Cancer and Us blog best viewed in Firefox

Thursday, January 05, 2012

Vermillion plans to reduce headcount, expenses - financial news (OVA1)

Vermillion Inc. VRML -2.76% plans to reduce its headcount and other expenses and focus on strengthening sales of its ovarian cancer testing product (OVA1)  this year.

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.